Literature DB >> 32966269

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.

Bezawit A Woldemeskel1, Abena K Kwaa1, Caroline C Garliss1, Oliver Laeyendecker1,2, Stuart C Ray1, Joel N Blankson1.   

Abstract

BACKGROUNDT cell responses to the common cold coronaviruses have not been well characterized. Preexisting T cell immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported, and a recent study suggested that this immunity was due to cross-recognition of the novel coronavirus by T cells specific for the common cold coronaviruses.METHODSWe used the enzyme-linked immunospot (ELISPOT) assay to characterize the T cell responses against peptide pools derived from the spike protein of 3 common cold coronaviruses (HCoV-229E, HCoV-NL63, and HCoV-OC43) and SARS-CoV-2 in 21 healthy donors (HDs) who were seronegative for SARS-CoV-2 and had no known exposure to the virus. An in vitro expansion culture assay was also used to analyze memory T cell responses.RESULTSWe found responses to the spike protein of the 3 common cold coronaviruses in many of the donors. We then focused on HCoV-NL63 and detected broad T cell responses to the spike protein and identified 22 targeted peptides. Interestingly, only 1 study participant had a significant response to SARS-CoV-2 spike or nucleocapsid protein in the ELISPOT assay. In vitro expansion studies suggested that T cells specific for the HCoV-NL63 spike protein in this individual could also recognize SARS-CoV-2 spike protein peptide pools.CONCLUSIONHDs have circulating T cells specific for the spike proteins of HCoV-NL63, HCoV-229E, and HCoV-OC43. T cell responses to SARS-CoV-2 spike and nucleocapsid proteins were present in only 1 participant and were potentially the result of cross-recognition by T cells specific for the common cold coronaviruses. Further studies are needed to determine whether this cross-recognition influences coronavirus disease 2019 (COVID-19) outcomes.

Entities:  

Keywords:  Adaptive immunity; Immunology; Infectious disease; T cells

Mesh:

Year:  2020        PMID: 32966269      PMCID: PMC7685719          DOI: 10.1172/JCI143120

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

3.  The time course of the immune response to experimental coronavirus infection of man.

Authors:  K A Callow; H F Parry; M Sergeant; D A Tyrrell
Journal:  Epidemiol Infect       Date:  1990-10       Impact factor: 2.451

Review 4.  What's New With the Old Coronaviruses?

Authors:  Chikara Ogimi; Yae Jean Kim; Emily T Martin; Hee Jae Huh; Cheng-Hsun Chiu; Janet A Englund
Journal:  J Pediatric Infect Dis Soc       Date:  2020-04-30       Impact factor: 3.164

5.  SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.

Authors:  Estela Giménez; Eliseo Albert; Ignacio Torres; María José Remigia; María Jesús Alcaraz; María José Galindo; María Luisa Blasco; Carlos Solano; María José Forner; Josep Redón; Jaime Signes-Costa; David Navarro
Journal:  J Med Virol       Date:  2020-07-02       Impact factor: 20.693

6.  SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential.

Authors:  Jason Neidleman; Xiaoyu Luo; Julie Frouard; Guorui Xie; Gurjot Gill; Ellen S Stein; Matthew McGregor; Tongcui Ma; Ashley F George; Astrid Kosters; Warner C Greene; Joshua Vasquez; Eliver Ghosn; Sulggi Lee; Nadia R Roan
Journal:  Cell Rep Med       Date:  2020-08-19

7.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.

Authors:  Alba Grifoni; Daniela Weiskopf; Sydney I Ramirez; Jose Mateus; Jennifer M Dan; Carolyn Rydyznski Moderbacher; Stephen A Rawlings; Aaron Sutherland; Lakshmanane Premkumar; Ramesh S Jadi; Daniel Marrama; Aravinda M de Silva; April Frazier; Aaron F Carlin; Jason A Greenbaum; Bjoern Peters; Florian Krammer; Davey M Smith; Shane Crotty; Alessandro Sette
Journal:  Cell       Date:  2020-05-20       Impact factor: 66.850

8.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Authors:  Feng-Cai Zhu; Yu-Hua Li; Xu-Hua Guan; Li-Hua Hou; Wen-Juan Wang; Jing-Xin Li; Shi-Po Wu; Bu-Sen Wang; Zhao Wang; Lei Wang; Si-Yue Jia; Hu-Dachuan Jiang; Ling Wang; Tao Jiang; Yi Hu; Jin-Bo Gou; Sha-Bei Xu; Jun-Jie Xu; Xue-Wen Wang; Wei Wang; Wei Chen
Journal:  Lancet       Date:  2020-05-22       Impact factor: 202.731

9.  Direct Observation of Repeated Infections With Endemic Coronaviruses.

Authors:  Marta Galanti; Jeffrey Shaman
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

10.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

View more
  27 in total

1.  SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.

Authors:  Bezawit A Woldemeskel; Caroline C Garliss; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

2.  Durability of SARS-CoV-2-Specific T-Cell Responses at 12 Months Postinfection.

Authors:  Zhongyan Lu; Eric D Laing; Jarina Pena DaMata; Katherine Pohida; Marana S Tso; Emily C Samuels; Nusrat J Epsi; Batsukh Dorjbal; Camille Lake; Stephanie A Richard; Ryan C Maves; David A Lindholm; Julia S Rozman; Caroline English; Nikhil Huprikar; Katrin Mende; Rhonda E Colombo; Christopher J Colombo; Christopher C Broder; Anuradha Ganesan; Charlotte A Lanteri; Brian K Agan; David Tribble; Mark P Simons; Clifton L Dalgard; Paul W Blair; Josh Chenoweth; Simon D Pollett; Andrew L Snow; Timothy H Burgess; Allison M W Malloy
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 7.759

3.  Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers.

Authors:  Ricardo da Silva Antunes; Suresh Pallikkuth; Erin Williams; Esther Dawen Yu; Jose Mateus; Lorenzo Quiambao; Eric Wang; Stephen A Rawlings; Daniel Stadlbauer; Kaijun Jiang; Fatima Amanat; David Arnold; David Andrews; Irma Fuego; Jennifer M Dan; Alba Grifoni; Daniela Weiskopf; Florian Krammer; Shane Crotty; Michael E Hoffer; Savita G Pahwa; Alessandro Sette
Journal:  J Infect Dis       Date:  2021-07-02       Impact factor: 5.226

4.  Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses.

Authors:  Arbor G Dykema; Boyang Zhang; Bezawit A Woldemeskel; Caroline C Garliss; Laurene S Cheung; Dilshad Choudhury; Jiajia Zhang; Luis Aparicio; Sadhana Bom; Rufiaat Rashid; Justina X Caushi; Emily Han-Chung Hsiue; Katherine Cascino; Elizabeth A Thompson; Abena K Kwaa; Dipika Singh; Sampriti Thapa; Alvaro A Ordonez; Andrew Pekosz; Franco R D'Alessio; Jonathan D Powell; Srinivasan Yegnasubramanian; Shibin Zhou; Drew M Pardoll; Hongkai Ji; Andrea L Cox; Joel N Blankson; Kellie N Smith
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

5.  Adaptive immunity to human coronaviruses is widespread but low in magnitude.

Authors:  Hyon-Xhi Tan; Wen Shi Lee; Kathleen M Wragg; Christina Nelson; Robyn Esterbauer; Hannah G Kelly; Thakshila Amarasena; Robert Jones; Graham Starkey; Bao Zhong Wang; Osamu Yoshino; Thomas Tiang; Michael Lindsay Grayson; Helen Opdam; Rohit D'Costa; Angela Vago; Laura K Mackay; Claire L Gordon; Adam K Wheatley; Stephen J Kent; Jennifer A Juno
Journal:  Clin Transl Immunology       Date:  2021-03-17

Review 6.  Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.

Authors:  Deborah Cromer; Jennifer A Juno; Stephen J Kent; Miles P Davenport; David Khoury; Arnold Reynaldi; Adam K Wheatley
Journal:  Nat Rev Immunol       Date:  2021-04-29       Impact factor: 53.106

7.  The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.

Authors:  Priyanka Shah; Gabriela A Canziani; Erik P Carter; Irwin Chaiken
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 8.786

Review 8.  Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility.

Authors:  Caterina Vicidomini; Valentina Roviello; Giovanni N Roviello
Journal:  Molecules       Date:  2021-03-26       Impact factor: 4.411

9.  Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths.

Authors:  Robert Root-Bernstein
Journal:  Vaccines (Basel)       Date:  2021-05-08

10.  Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects.

Authors:  Eleonora Gallerani; Davide Proietto; Beatrice Dallan; Marco Campagnaro; Salvatore Pacifico; Valentina Albanese; Erika Marzola; Peggy Marconi; Antonella Caputo; Victor Appay; Riccardo Gavioli; Francesco Nicoli
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.